Navigation Links
Nanomedical Diagnostics to Present Field Effect Biosensing for Fragment-Based Drug Discovery at SLAS 2017
Date:1/24/2017

Nanomedical Diagnostics, a biotech company pioneering the development of label-free graphene biosensor assays for fragment-based screening, will showcase its proprietary Field Effect Biosensing (FEB) technology in booth 1317 at the 2017 Society for Laboratory Automation and Screening (SLAS) conference in Washington, D.C. from Feb. 6 to Feb. 8.

Fragment-based drug discovery (FBDD) is increasingly used in the pharmaceutical industry as a complementary approach to traditional high-throughput screening (HTS). As opposed to HTS libraries of one-million small molecule compounds, FBDD screens can contain just 2000 low molecular weight fragments. In FBDD, researchers employ label-free biophysical techniques such as surface plasmon resonance (SPR), nuclear magnetic resonance (NMR) spectroscopy, and X-ray crystallography as primary screening methodologies, but the low molecular weight of fragments and the solvents used to dissolve them can hinder accurate hit identification.

Nanomedical Diagnostics will introduce a real-time, label-free detection method that is based on electronics, providing a strong orthogonal approach for screening and hit validation. FEB excels in detecting molecules with large charge-to-mass ratios which enables sensing of compounds with no lower size limit, a considerable benefit in fragment-based screening. The non-optical technique measures the current across a field effect surface to which the target is immobilized. Any interaction or binding that occurs on the biosensor surface causes a change in conductance that is monitored in real time, providing accurate kinetic and affinity data.

“Because Field Effect Biosensing measures electrical changes instead of mass, the technology can sense in solutions such as DMSO which cause a high level of background noise on optical sensors. We have detected in 10% DMSO with no effect,” says Nanomedical Diagnostics CEO, Ross Bundy. “This provides an excellent alternate methodology for researchers who struggle to measure in complex solvents that are necessary for their candidate compounds.”

The small size of FEB technology lends to high-throughput when coupled with automatic liquid handling systems. “We estimate that a 3000-compound fragment library can be screened in one eight-hour shift on a single 96-well system,” continues Mr. Bundy. “Combined with the wide dynamic range of the platform, FEB technology can be used not only for hit identification, but also for assay development and lead optimization. The ability to use the same methodology across the drug discovery process vastly reduces assay optimization time, enabling a shorter timeline to preclinical trials.”

At SLAS2017, Nanomedical Diagnostics will showcase FEB technology with its first product, AGILE R100. For more information, visit http://www.nanomedicaldiagnostics.com.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding and affinity data. Biosensors at the heart of the assay leverage the highly sensitive nanomaterial graphene to unite biology with electronics, delivering the unique ability to sense molecules with no lower size limit in complex media such as DMSO, and use unprecedentedly small amounts of sample.

Read the full story at http://www.prweb.com/releases/Nanomedical_Diagnostics/SLAS2017/prweb14007568.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Nanomedical Diagnostics Announces Scientific Advisory Board of Top Scientists and Medical Researchers
2. Nanomedical Diagnostics launches a new graphene biosensor with unprecedented functionality for small molecule and protein analysis
3. Nanomedical Diagnostics CEO and CTO to Introduce Electronic Label-Free Assay Based on Field Effect Biosensing Technology at IDTechEx Show
4. DMG is Proud to Announce that CD Diagnostics will be Featured in an Upcoming Episode of Health Heroes
5. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
6. PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
7. Dominion Diagnostics to Sponsor 2013 Addiction Professional Panel Series as Thought Leadership Partner
8. MGC Diagnostics Corporation Announces Special Cash Dividend and Extension of Stock Repurchase Program
9. Slone Partners CEO & President Speak about Hiring Challenges in Molecular Diagnostics at Executive War College 2013
10. Advanced Animal Diagnostics Raises $6 Million for On-farm Diagnostics
11. Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
(Date:10/7/2017)... 2017  The 2017 Nobel Prize in Chemistry ... Dubochet, Joachim Frank and Richard ... microscopy (cryo-EM) have helped to broaden the ... community. The winners worked with systems manufactured by ... highly resolved, three-dimensional images of protein structures that ...
(Date:10/6/2017)... Washington, D.C. (PRWEB) , ... October 06, 2017 ... ... Cure) will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive ... INSIGhT Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to ...
(Date:10/5/2017)... PA (PRWEB) , ... October 05, 2017 , ... Understanding ... the newest frontiers in human health. Gut Love: You Are My Future, the newest ... an artist’s perspective as it explores the human condition through the lens of the ...
Breaking Biology Technology:
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):